Latest News about AMGN
Recent news which mentions AMGN
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
From Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
From Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
From Motley Fool
2 Reliable Dividend Stocks You Can Buy and Hold Forever
October 26, 2024
From Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
From Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Amgen
October 14, 2024
Tickers
AMGN
From Benzinga
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
From Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
October 11, 2024
From Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
October 10, 2024
From Benzinga
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
October 10, 2024
From Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
October 09, 2024
From Motley Fool
From Motley Fool
3 Magnificent Dividend Stocks to Buy in October
October 06, 2024
From Motley Fool
Should You Buy the Dip on This Top Growth Stock?
October 05, 2024
From Motley Fool
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
October 02, 2024
From Benzinga
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
From Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
From Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
From Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
From Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
September 24, 2024
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.